PBP1510 (INN: Ulenistamab)

PBP1510 is a first-in-class monoclonal antibody drug developed by Prestige Biopharma Limited against pancreatic adenocarcinoma up-regulated factor (PAUF), a protein that is overexpressed in pancreatic adenocarcinoma. PAUF is involved in promoting tumor growth, invasion, and metastasis, in the evasion of immune surveillance, and contributes to the generation of an immunosuppressive tumor microenvironment (TME). Neutralization by PBP1510 attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells and TME.

PBP1510 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Ministry of Food and Drug Safety (MFDS) in Korea, as well as Fast Track Designation by FDA.
It is currently undergoing Phase 1/2a clinical trials in the U.S., Europe, Asia, and Australia.